Results 221 to 230 of about 112,622 (301)

'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer. [PDF]

Biochem Soc Trans
Buckley-Benbow L, Agnarelli A, Bellelli R.   +2 more
europepmc   +1 more source

A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model‐Based Economic Evaluation

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 4, Page 680-689, March 2026.
ABSTRACT Objective To assess the costs and consequences of seven diagnostic strategies for ovarian cancer in pre‐ and post‐menopausal women with symptoms in secondary care. Design Economic evaluation alongside a prospective single‐arm diagnostic accuracy study.
Samuel J. Perry, Donal Griffin, Eleanor V. Williams, Tracy E. Roberts, Fong Lien Kwong, Sarah Williams, Jon Deeks, Katie Scandrett, Ridhi Agarwal, Sudha S. Sundar, Mark Monahan   +10 more
wiley   +1 more source

EXO1 overexpression induces homologous recombination deficiency and enhances PARP inhibitor sensitivity in ER-positive breast cancer: modulation by N4BP2L2-Mediated restoration. [PDF]

Front Cell Dev Biol
Sugiyama R, Sedukhina AS, Sato E, Yamaura A, Minagawa K, Pae S, Imai E, Chawla A, Xu Z, Chakraborty M, Gonoi S, Yamaoka J, Yudo K, Tsugawa K, Sato K.   +14 more
europepmc   +1 more source

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background The expansion of treatment options for prostate cancer (PC) has improved disease‐specific and overall survival outcomes but has also raised questions about the optimal level of treatment needed for patients based on their individual prognosis and accounting for potential toxicity, incorporating quality of life considerations ...
Rana R. McKay, Benjamin L. Maughan, Alicia K. Morgans, Neal D. Shore, Evan Y. Yu, Ravi A. Madan, Jacob E. Berchuck, Bradley C. Carthon, Steven E. Finkelstein, Leonard Gomella, Michael A. Gorin, Andrew W. Hahn, Stacy Loeb, Vivek K. Narayan, Daniel P. Petrylak, Charles J. Ryan, Karine Tawagi, Phuoc T. Tran, Tanya Dorff   +18 more
wiley   +1 more source

Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor. [PDF]

ESMO Open
Kim JH, Lim MC.
europepmc   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, Volume 16, Issue 2, Page 432-446, February 2026.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [PDF]

EJNMMI Res
Weng CC, Chiang CC, Chung YH, Ho YP, Chang YC, Hsiao IT, Mach RH.   +6 more
europepmc   +1 more source

ACSL5 Regulates Glucose Metabolism and Chemotherapy Sensitivity in Colorectal Cancer Cells under Glutamine Deficiency

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Glutamine deprivation triggers ACSL5 upregulation in tumor cells, sustaining their viability via dual metabolic rewiring programs. ACSL5 enhances glycolysis by relieving p53's inhibition of PGAM1 while also sustaining mitochondrial respiration and TCA cycle flux through promoting IDH2 dimerization.
Shuai Tian, Qiaoxia Zhang, Xuedan Sun, Rick Francis Thorne, Zeyuan Shi, Qiang Ji, Zhangran Sun, Yuanxiang Lu, Qun Zhao, Xianjun Yu, Wanglai Hu, Mian Wu   +11 more
wiley   +1 more source

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models. [PDF]

Nat Commun
Kyula-Currie J, Roulstone V, Wright J, Butera F, Legrand A, Elliott R, McLaughlin M, Bozhanova G, Krastev D, Pettitt S, Tenev T, Dillon M, Foo S, Patin EC, Jennings V, Chan Wah Hak C, Appleton E, Wongariyapak A, Pedersen M, Rullan A, Choudhary J, Bakal C, Meier P, Lord CJ, Melcher A, Harrington KJ.   +25 more
europepmc   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, Volume 13, Issue 8, 9 February 2026.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source